Pharmaceuticals, Biotechnology and Life Sciences
Total product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended March 31, 2020; Jakafi® (ruxolitinib) revenues of $459 million in Q1 2020 (+22% vs Q1 2019).
Incyte last week named new Canada Biosciencess head, announcing establishing key development and commercialization capabilities in preparation for potential launches of multiple products in the near future.
MONTREAL–(BUSINESS WIRE)–$INCY—Incyte (Nasdaq:INCY) has appointed Christine Lennon as the General Manager for Incyte Biosciences Canada, expanding the its North American…
Novartis said on Thursday it aims to start a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for the treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19.
Incyte has treated first vitiligo patient in its phase 3 clinical trial testing ruxolitinib cream as a monotherapy for older patients older than 12.
WILMINGTON, Del. & SHANGHAI–(BUSINESS WIRE)–$INCY–Incyte (NASDAQ:INCY) and Zai Lab Ltd. (NASDAQ:ZLAB) today announced that the companies have entered into a…
Jakafi is the first and only FDA-approved treatment for patients with
steroid-refractory acute graft-versus-host disease (GVHD)
Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the…
–(BUSINESS WIRE)–Incyte is a global biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to meet serious…
Bristol-Myers Squibb and Incyte Corporation will evaluate combination of epacadostat with Opdivo in advancing a clinical development program into phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.